Publication

Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair (HRR) gene mutation status: Overall survival (OS) results from the ORZORA study

Pignata, S.
; 
Oza, A. M.
; 
Hall, G.
; 
Pardo, B.
; 
Madry, R.
; 
Cibula, D.
; 
Klat, J.
; 
Montes, A.
; 
Glasspool, R.
; 
Colombo, N.
... show 10 more
Citations
Altmetric:
Abstract
Authors
Pignata, S.
Oza, A. M.
Hall, G.
Pardo, B.
Madry, R.
Cibula, D.
Klat, J.
Montes, A.
Glasspool, R.
Colombo, N.
Pete, I.
Herrero, A.
Romeo, M.
Ilieva, R. N.
Timcheva, C.
Di Maio, M.
Barnicle, A.
Taylor, R.
Bashir, Z.
Clamp, Andrew R
Affiliation
Istituto Nazionale Tumori ‘Fondazione G Pascale’, IRCCS, Napoli, Italy
Description
Date
2022
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Pignata S, Oza AM, Hall G, Pardo B, Madry R, Cibula D, et al. Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair (HRR) gene mutation status: Overall survival (OS) results from the ORZORA study. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301572.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/625807
Embedded videos